Compositions and methods for elimination of unwanted cells

Details Compositions and methods for elimination of unwanted cells Compositions and methods for elimination of unwanted cells

2008-01-01

2008-01-01

Chen, Shin-Lin (Department: 1632)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C435S320100, C435S455000, C536S023100, C536S023400, C536S023720

Reexamination Certificate

active

07314868

ABSTRACT:
Disclosed are compositions comprising a recombinant nucleic acid vector including a nucleotide sequence encoding a syncytium-inducing polypeptide expressible on a eukaryotic cell surface, and a host cell containing the recombinant vector and expressing the syncytium inducing polypeptide on its cell surface, the vectors and resultant host cells expressing the syncytium inducing polypeptide being useful for selective elimination of unwanted cells.

REFERENCES:
patent: 5753499 (1998-05-01), Meruelo et al.
patent: 5847096 (1998-12-01), Schubert et al.
patent: 5869036 (1999-02-01), Belshe et al.
patent: 6750206 (2004-06-01), Russell et al.
patent: WO 96/30030 (1996-03-01), None
patent: WO 97/03357 (1997-01-01), None
Stieneke-Grober et al., 1992, The EMBO Journal, vol. 11, No. 7, pp. 2407-2414.
Davis, C. G., 1990, The New Biologist, vol. 2, No. 5, p. 410-419.
Jia et al., 2005, Current Gene Therapy, vol. 5, p. 133-142.
Nakamura, T., et al., “Antibody-targeted cell fusion” Nature Biotechnology, vol. 22(3):331-336 (2004).
ATCC HTB 30, Human Tumor Cell Bank, pp. 222-223.
Andeweg et al., “Both the V2 and V3 Regions of the Human Immunodeficiency Virus Type 1 Surface Glycoprotein Functionally Interact with Other Envelope Regions in Syncytium Formation,”J. Virol., 1993, 67:3232-3239.
Asada, “Treatment of Human Cancer with Mumps Virus,”Cancer, 1974, 34:1907-1928.
Ausubel et al. (eds.),Current Protocols in Molecular Biology, 1989, Greene Publishing Associates, Sections 9.10-9.14.
Baghian et al., “Truncation of the Carboxy-Terminal 28 Amino Acids of Glycoprotein B Specified by Herpes Simplex Virus Type 1. Mutantamb1511-7 Causes Extensive Cell Fusion,”J. Virol., 1993, 67:2396-2401.
Berkner et al.,BioTechniques, 1988, 6:616.
Briozzo et al., “In Vitro Degradation of Extracellular Matrix withM, 52,000 Cathepsin D Secreted by Breast Cancer Cells,”Cancer Res., 1988, 48:3688-3692.
Brody et al., “Postassembly Cleavage of a Retroviral Gycoprotein Cytoplasmic Domain Removes a Necessary Incorporation Signal and Activates Fusion Activity,”J. Virol., 1994, 68:4620-4627.
Cai et al., “Role of Glycoprotein B of Herpes Simplex Virus Type 1 in Viral Entry and Cell Fusion,”J. Virol., 1988, 62:2596-2604.
Cathomen et al., “Preferential Inititation at the Second AUG of the Measles Virus F mRNA: A Role for the Long Untranslated Region,”Virology, 1995, 214:628-632.
Ciambrone and McKeown-Longo, “Vitronectin Regulates the Synthesis and Localization of Urokinase-type Plasminogen Activator in HT-1080 Cells,”J. Biol. Chem., 1992, 267:13617-13622.
Cohen et al., “Biological effects of prostate specific antigen as an insulin-like growth factor binding protein-3 protease,”J. Endocrinol., 1994, 142:407-415.
Cosset et al., “Retroviral Retargeting by Envelopes Expressing an N-Terminal Binding Domain,”J. Virol., 1995, 69:6314-6322.
Cosset et al., “High-Titer Packaging Cells Producing Recombinant Retroviruses Resistant to Human Serum,”J. Virol., 1995, 69:7430-7436.
Cosset and Russell, “Targeting retrovirus entry,”Gene Therapy, 1996, 3:946-956.
Crystal, “Transfer of Gene to Human Early Lessons and Obstacles to Success,”Science, 1995, 270:404-410.
Danø et al., “Plasminogen Activators, Tissue Degradation, and Cancer,”Adv. Cancer Res., 1985, 44:139-266.
Daya et al., “Cholesterol Enhances Mouse Hepatitis Virus-Mediated Cell Fusion,”Virol., 1988, 163:276-283.
Denesvre et al., “TM Domain Swapping of Murine Leukemia Virus and Human T-Cell Leukemia Virus Envelopes Confers Different Infectious Abilities despite Similar Incorporation into Virions,”J. Virol., 1996, 70:4380-4386.
Deonarain, “Ligand-targeted receptor-mediated vector for gene delivery,”Exp. Opin. Ther. Pat., 1998, 8:53-69.
Durrant et al., “Antigenicity of newly established colorectal carcinoma cell lines,”Br. J. Cancer, 1986, 53:37-45.
Duus et al., “Cell Surface Expression and Fusion by the Varicella-Zoster Virus gH:gL Glycoprotein Complex: Analysis by Laser Scanning Confocal Microscopy,”Virology, 1995, 210:429-440.
Dvorak, “Thrombosis and Cancer,”Hum. Pathol., 1987, 18:275-284.
Eck et al., “Gene-Based Therapy,”Goodman&Gildman's The Pharmacological Basis of Therapeutics, 1996, 9th Edition, Chapter 5, pp. 77-101.
Edwards et al., “Human Tumor Procoagulants: Registry of the Subcommittee on Haemostasis and Malignancy of the Scientific and Standardization Committee, International Society on Thrombosis and Haemostasis,”Throm. Haemostasis, 1993, 69:205-213.
Forrester et al., “Construction and Properties of a Mutant of Herpes Simplex Virus Type 1 with Glycoprotein H Coding Sequences Deleted,”J. Virol., 1992, 66:341-348.
Gage et al., “Syncytium-Inducing Mutations Localize to Two Discrete Regions within the Cytoplasmic Domain of Herpes Simplex Virus Type 1 Glycoprotein B,”J. Virol., 1993, 67:2191-2201.
Gething et al., “Studies on the Mechanism of Membrane Fusion: Site-specific Mutagenesis of the Hemagglutinin of Influenza Virus,”J. Cell. Biol., 1986, 102:11-23.
Gong et al., “Vaccinia Virus Induces Cell Fusion at Acid pH and This Activity Is Mediated by the N-Terminus of the 14-kDa Virus Envelope Protein,”Virology, 1990, 178:81-91.
Gordon and Cross, “A Factor X-Activating Cysteine Protease from Malignant Tissue,”J. Clin. Invest., 1981, 67:1665-1671.
Heminway et al., “Analysis of Respiratory Syncytial Virus F, G, and SH Proteins in Cell Fusion,”Virology, 1994, 200:801-805.
Hermonat et al., “Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells,”Proc. Natl. Acad. Sci. USA, 1984, 81:6466-6470.
Ichihashi and Dales, “Biogenesis of Poxviruses: Interrelationship between Hemagglutinin Production and Polykaryocytosis,”Virology, 1971, 46:533-543.
Ichinose et al., “The Activation of Pro-urokinase by Plasma Kallikrein and Its Inactivation by Thrombin,”J. Biol. Chem., 1986, 261:3486-3489.
Kaye et al., “A single amino acid substitution results in a retinoblastoma protein defective in phosphorylation and oncoprotein binding,”Proc. Natl. Acad. Sci. USA, 1990, 87:6922-6926.
Kessler and Markus, “Epidermal Growth Factor and 12-Tetradecanoyl Phorbol 13-Acetate Induction of Urokinase in A431 Cells,”Sermin, Thromb. Hemostasis, 1991, 17:217-224.
Koivunen et al., “Human Ovarian Tumor-associated Trypsin Its Purification and Characterization from Mucinous Cyst Fluid and Identification As An activator of Pro-Urokinase,”J. Biol. Chem., 1989, 264:14095-14099.
Laug et al., “Clonal Variation of Expression of the Genes Coding for Plasminogen Activators, Their Inhibitors and the Urokinase Receptor in HT1080 Sarcoma Cells,”Int. J. Cancer, 1992, 52:298-304.
Lilja et al., “Seminal Vesicle-secreted Proteins and Their Reactions during Gelation and Liquefaction of Human Semen,”J. Clin. Invest., 1987, 80:281-285.
Lund et al., “Urokinase-receptor biosynthesis, mRNA level and gene transcription are increased by transforming growth factor β1 in human A549 lung carcinoma cells,”EMBO J., 1991, 10:3399-3407.
Miller and Vile, “Targeted vectors for gene therapy,”FASEB J., 1995, 9:190-199.
Miller, “Progress Toward Human Gene Therapy,”Blood, 1990, 76:271-278.
Mulligan et al., “Cytoplasmic Domain Truncation Enhances Fusion Activity by the Exterior Glycoprotein Complex of Human Immunodeficiency Virus Type 2 in Selected Cell Types,”J. Virol., 1992, 66:3971-3975.
Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,”Current Topics in Microbiology and Immunology, 1992, 158:97-129.
Nilson et al., “Targeting of retroviral ve

Affiliated with

Also associated with

Rating

Compositions and methods for elimination of unwanted cells does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compositions and methods for elimination of unwanted cells, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for elimination of unwanted cells will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2797811